Laboratorios Farmaceúticos Rovi SA (LABFF)
65.86
0.00 (0.00%)
USD |
OTCM |
Jun 09, 16:00
Laboratorios Farmaceúticos Rovi Price to Book Value : 4.339 for June 9, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| June 09, 2026 | 4.339 |
| June 08, 2026 | 4.339 |
| June 05, 2026 | 4.339 |
| June 04, 2026 | 4.339 |
| June 03, 2026 | 4.339 |
| June 02, 2026 | 4.339 |
| June 01, 2026 | 4.339 |
| May 29, 2026 | 4.339 |
| May 28, 2026 | 4.339 |
| May 27, 2026 | 4.339 |
| May 26, 2026 | 4.339 |
| May 22, 2026 | 4.339 |
| May 21, 2026 | 4.339 |
| May 20, 2026 | 4.339 |
| May 19, 2026 | 4.339 |
| May 18, 2026 | 4.339 |
| May 15, 2026 | 4.339 |
| May 14, 2026 | 4.339 |
| May 13, 2026 | 4.339 |
| May 12, 2026 | 4.339 |
| May 11, 2026 | 4.339 |
| May 08, 2026 | 4.339 |
| May 07, 2026 | 4.339 |
| May 06, 2026 | 4.339 |
| May 05, 2026 | 4.339 |
| Date | Value |
|---|---|
| May 04, 2026 | 4.339 |
| May 01, 2026 | 4.339 |
| April 30, 2026 | 4.339 |
| April 29, 2026 | 4.339 |
| April 28, 2026 | 4.339 |
| April 27, 2026 | 5.969 |
| April 24, 2026 | 4.339 |
| April 23, 2026 | 4.339 |
| April 22, 2026 | 4.339 |
| April 21, 2026 | 4.339 |
| April 20, 2026 | 4.339 |
| April 17, 2026 | 4.339 |
| April 16, 2026 | 4.339 |
| April 15, 2026 | 4.339 |
| April 14, 2026 | 4.339 |
| April 13, 2026 | 4.339 |
| April 10, 2026 | 4.339 |
| April 09, 2026 | 4.339 |
| April 08, 2026 | 4.339 |
| April 07, 2026 | 4.339 |
| April 06, 2026 | 4.339 |
| April 02, 2026 | 4.339 |
| April 01, 2026 | 4.339 |
| March 31, 2026 | 4.339 |
| March 30, 2026 | 4.317 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Almirall SA | 1.794 |
| AstraZeneca PLC | 11.72 |
| ANI Pharmaceuticals, Inc. | 3.328 |
| Corcept Therapeutics, Inc. | 13.15 |
| Assertio Holdings, Inc. | 2.001 |
Price to Book Value Related Metrics
| PE Ratio | 22.01 |
| PS Ratio | 3.919 |
| PEG Ratio | 15.57 |
| Price to Free Cash Flow | 25.54 |
| Price | 65.86 |
| Earnings Yield | 4.54% |
| Market Cap | 3.369B |
| PEGY Ratio | 7.161 |
| Operating PE Ratio | 18.12 |
| Normalized PE Ratio | 22.02 |